Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | DUT | P33316 | 1/20 | 0.38 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198357 | 1.00 | NT5E (0.41) | NT5ETDP1DUTSMYD2LMNA | |
| SCHEMBL18503494 | 0.92 | NT5E (0.42) | NT5ETDP1DUTSMYD2P2RY2 | |
| SCHEMBL18503499 | 0.92 | NT5E (0.42) | NT5ETDP1DUTSMYD2P2RY2 | |
| SCHEMBL17198350 | 0.82 | SLC28A1 (0.44) | NT5ETDP1LMNATHRBSMN1; SMN2 | |
| SCHEMBL17198440 | 0.80 | TDP1 (0.43) | TDP1DUTLMNATHRBSMN1; SMN2 | |
| SCHEMBL17198356 | 0.80 | LMNA (0.37) | SMYD2LMNA | |
| SCHEMBL13722085 | 0.79 | TDP1 (0.38) | NT5ETDP1DUTSMYD2LMNA | |
| SCHEMBL17198400 | 0.79 | SLC28A1 (0.45) | P2RY2P2RY14P2RY6 | |
| SCHEMBL17198648 | 0.79 | SLC28A1 (0.45) | P2RY2P2RY14P2RY6 | |
| SCHEMBL18512781 | 0.78 | TDP1 (0.43) | NT5ETDP1DUTLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | NT5E 1352/4885TDP1 625/4885DUT 208/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | NT5E 1275/4885TDP1 635/4885DUT 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.